Scholars Central

Conference abstractPublished 23 Sep 2013

Clearing the biosimilar patent thicket with IPRs

Authors: Kevin W. McCabe

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It is well recognized that most licensed biologic products are covered by a multitude of patents. The biosimilars regime created a defined pathway to identify and litigate the patents covering a licensed product as part of a biosimilar challenge. The recent implementation of the America Invents Act provides further mechanisms to challenge patents outside of the courts. These mechanisms, notably an inter partes review or post grant review, have many advantages that should be understood by those contemplating or expecting a biosimilars challenge.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Kevin W. McCabe”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels